Abstract
Nanotechnology offers invaluable tools to tailor cancer vaccines in order to generate robust antitumor immune response. Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability. Several nanostructures have been discussed in literature as potential delivery systems for cancer antigens. Here, we focus on polymeric NPs fabricated from poly(d,l-lactic-co-glycolic) acid (PLGA). We describe how to prepare and characterize such NPs loaded with ovalbumin (OVA) antigen and immune adjuvant monophosphoryl lipid A (MPLA). We further describe methods to test the immune efficacy of such NPs in vitro and in vivo.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Schuster M, Nechansky A, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1(2):138–147. doi:10.1002/biot.200500044
Hamdy S, Alshamsan A, Samuel J (2009) Nanotechnology for cancer vaccine delivery, Nanotechnology in drug delivery. Springer, New York, pp 519–543
Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10:3. doi:10.1186/1476-4598-10-3
Fan Y, Moon JJ (2015) Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 3(3):662–685. doi:10.3390/vaccines3030662
Li W, Wei H, Li H, Gao J, Feng SS, Guo Y (2014) Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine 9(16):2587–2605. doi:10.2217/nnm.14.127
Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63(10–11):943–955. doi:10.1016/j.addr.2011.05.021
Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J (2007) “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother 30(4):378–395. doi:10.1097/CJI.0b013e31802cf3e3
Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ (2009) Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8(2):151–158. doi:10.1038/nmat2357
Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223(1):77–92
Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J (2007) Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 81(3):652–662. doi:10.1002/jbm.a.31019
Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26(39):5046–5057. doi:10.1016/j.vaccine.2008.07.035
Weinstein Y, Ran S, Segal S (1984) Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol 132(2):656–661
Kishimoto S, Tsuyuguchi I, Yamamura Y (1969) Immune responses in aged mice. Clin Exp Immunol 5(5):525–530
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63
Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L (2004) Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD
Acknowledgment
This work was supported by King Abdullah Institute for Nanotechnology and the Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Alshamsan, A. (2017). Nanotechnology-Based Cancer Vaccine. In: Zeineldin, R. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 1530. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6646-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6646-2_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6644-8
Online ISBN: 978-1-4939-6646-2
eBook Packages: Springer Protocols